India Approves Takeda's QDENGA, Its First Dengue Vaccine, Amid 11-Fold Surge in Cases
核心洞察
India's drug regulator has approved Takeda (搜索)'s QDENGA, the country's first dengue (搜索) vaccine, for use in individuals aged 4–60 years.
The tetravalent live-attenuated vaccine protects against all four dengue (搜索) serotypes and does not require pre-vaccination testing, unlike earlier vaccines.
A local Phase 3 study in 480 healthy adults confirmed the vaccine was tolerated, safe, and immunogenic; Takeda (搜索) must conduct a post-marketing safety study within six months.
In a landmark decision for India's public health, the country's drug regulator has approved Takeda (搜索)'s QDENGA (also stylized as Qdenga), making it the first dengue (搜索) vaccine ever authorized for use in India. The approval, granted last week, comes as the nation grapples with an 11-fold increase in dengue cases over the past two decades, with more than 1.1 lakh cases reported last year alone.
India accounts for nearly one-third of the global dengue (搜索) burden, and all four dengue virus serotypes have been documented as co-circulating in several regions, making the arrival of a broadly protective vaccine a critical development.
A Tetravalent Vaccine Without Pre-Vaccination Testing
QDENGA is a tetravalent live-attenuated vaccine designed to induce a strong immune response by generating detectable antibodies against all four dengue (搜索) virus serotypes—DENV-1, DENV-2, DENV-3, and DENV-4. The two-dose vaccine is recommended for the 4–60 age group.
A key differentiator from Sanofi's Dengvaxia (CYD-TDV) is that QDENGA can be administered regardless of prior dengue (搜索) exposure and does not require pre-vaccination testing, simplifying its deployment in endemic regions.
Local Clinical Evidence and Post-Marketing Requirements
The Indian approval is supported by a local Phase 3 study involving 480 healthy adults, in which the vaccine was found to be "tolerated, safe and immunogenic" across the target age group. As a condition of approval, Takeda (搜索) is required to conduct a post-marketing safety and effectiveness study in the local population within six months of introducing the vaccine to the market.
Globally, Takeda (搜索) has conducted nine Phase 3 trials, six Phase 2 trials, and five Phase 1 trials, enrolling more than 28,000 volunteers from dengue (搜索)-endemic and non-endemic regions, covering an age range from 1.5 to 60 years. The TIDES study demonstrated up to seven years of protection against all four dengue virus serotypes.
Global Reach and Manufacturing Scale-Up
Since its global launch in 2022, QDENGA has received approval in 43 countries, with more than 32 million doses distributed worldwide, according to Dr. Mahender Nayak, Head of Intercontinental Markets at Takeda (搜索). The vaccine has also received prequalification from the World Health Organization (WHO), positioning it as a preferred candidate for inclusion in public vaccination programs.
In 2024, Takeda (搜索) partnered with Hyderabad-based Biological E (搜索) to expand manufacturing capacity. Under the agreement, Biological E plans to build capacity to manufacture 50 million doses annually, contributing to Takeda's global target of producing 100 million doses per year by the end of the decade.
Expert Perspectives and Next Steps
"India carries a substantial dengue (搜索) burden, and all four dengue virus serotypes have been documented as co-circulating in several regions. Qdenga represents an important step in strengthening comprehensive approach to dengue prevention, alongside vector control, surveillance and other public health measures," said Dr. Goh Choo Beng, Medical Affairs Head Southeast Asia and India Cluster, Takeda (搜索).
While the regulatory approval marks a major milestone, experts note that wider rollout will depend on pricing, supply, recommendations from India's immunization and public health authorities, and integration into existing dengue (搜索) prevention strategies. If deployed at scale, the vaccine could significantly strengthen India's fight against a disease that continues to affect lakhs of people annually and remains a major seasonal public health challenge.